ERBB2 and cancer: In light of our findings that EGR4-S decreases with HER2 inhibition in cells sensitive to HER2 inhibitors, our studies indicate that EGR4-S has potential value as a biomarker for tracking TKI drug responsiveness in HER2+ cancer cells.